99 completed, 30 unknown, 26 recruiting, 16 not yet recruiting. 207 Phase 2, 35 Phase 3, 29 Phase 1.
Follow Tablets: new trials by email Literature Review of Tablets trials Research Report on Tablets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Fosamprenavir for GERD Fosamprenavir Calcium 700 MG Oral Tablet, Placebo - Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 60 | 2027-10-01 | 2026-09-10 |
| Validation & Intervention Testing for Aging, Longevity and Healthspan Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo - Aging, Functional Decline | Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 1200 | 2027-01-01 | 2026-11-06 |
| Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 84 | 2026-11-02 | 2026-11-05 |
| T4/T3 Therapy in Hypothyroidism Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo - Hypothyroidism Primary | Phase 2 | Not yet recruiting | University of Pennsylvania | 60 | 2026-11-01 | 2026-08-20 |
| Colchicine in Pulmonary Artery Hypertension Patients Colchicine 0.5 MG Oral Tablet - Pulmonary Hypertension | Phase 2 | Not yet recruiting | Ain Shams University | 60 | 2026-10-31 | 2026-10-30 |
| Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Colchicine 0.5 MG Oral Tablet, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria di Modena | 87 | 2026-10-01 | 2026-09-10 |
| Bempedoic Acid Therapy for Polycystic Kidney Disease Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s) - ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 2 | Recruiting | Kenneth Hallows | 120 | 2026-09-01 | 2026-09-29 |
| Pirfenidone as Treatment of Chronic Pancreatitis Pirfenidone 267 mg Oral Tablet, Placebo, PROMIS-Global Health - Chronic Pancreatitis | Phase 2 | Not yet recruiting | Vikas Dudeja | 60 | 2026-08-01 | 2026-08-10 |
| A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment Avatrombopag 20 mg Oral Tablet - Aplastic Anemia | Phase 2 / Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 26 | 2026-07-31 | 2026-08-26 |
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis Roflumilast 500 Mcg Oral Tablet, Placebo Group - Rheumatoid Arthritis, Rheumatoid Arthritis (RA) | Phase 2 | Recruiting | Horus University | 50 | 2026-05-19 | 2026-06-08 |
| MTOR Inhibitors in Older Adults Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet - Aging | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-05-11 | 2026-06-25 |
| Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction Montelukast 10 Mg Oral Tablet, placebo - Acute Myocardial Infarction (AMI) | Phase 2 | Recruiting | October 6 University | 80 | 2026-04-20 | 2026-05-08 |
| EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL. Methotrexate, Roflumilast 500 Mcg Oral Tablet - Flexural Psoriasis (Also Known as Inverse or Intertriginous Psoriasis) and Genital Psoriasis | Phase 2 | Not yet recruiting | Eman Raafat Said | 56 | 2026-04-01 | 2026-04-22 |
| Neuroprotection of Memantine and Rosuvastatin Starch Placebo, Memantine, Rosuvastatin 20 Mg Oral Tablet - Peripheral Nerve Disease | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 46 | 2026-03-01 | 2026-03-31 |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) Everolimus (Afinitor) tablets - Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2026-03-01 | 2026-02-27 |
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC) - HIV Infections | Phase 2 | Recruiting | ViiV Healthcare | 186 | 2026-02-11 | 2026-11-12 |
| Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer Abemaciclib 150 MG Oral Tablet - ctDNA Monitoring, Breast Cancer | Phase 2 | Not yet recruiting | Nagoya City University | 30 | 2026-01-10 | 2025-12-18 |
| Novel Treatment of Radiation Associated Dysphagia With Statins Pravastatin 40 Mg Oral Tablet - Radiation-associated Dysphagia, Head &Amp; Neck Cancer | Phase 2 | Recruiting | Peter MacCallum Cancer Centre, Australia | 48 | 2025-12-05 | 2026-09-04 |
| Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study Oral roflumilast - Atopic Dermatitis | Phase 2 | Recruiting | Nora Mohamed Abdelrazik | 36 | 2025-11-20 | 2025-12-30 |
Showing 20 of 207. Sign in to see all of them.
Breast Neoplasms (11) · Obesity (6) · Renal Insufficiency, Chronic (5) · Attention Deficit Disorder with Hyperactivity (4) · Cardiovascular Diseases (4) · HIV Infections (4) · Melanoma (4) · Non-alcoholic Fatty Liver Disease (4) · Polycystic Ovary Syndrome (4) · Acquired Immunodeficiency Syndrome (3) · Agnosia (3) · Alzheimer Disease (3) · COVID-19 (3) · Depressive Disorder, Major (3) · Diabetes Mellitus (3)
GlaxoSmithKline (7) · Tanta University (5) · Ain Shams University (4) · Point Therapeutics (4) · Benha University (3) · Massachusetts General Hospital (3) · University of North Carolina, Chapel Hill (3) · ANRS, Emerging Infectious Diseases (2) · Alfasigma S.p.A. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Cassava Sciences, Inc. (2) · Fudan University (2) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (2) · H. Lundbeck A/S (2) · Jennifer Keiser (2)
United States (62) · Egypt (21) · China (16) · Canada (13) · Italy (11) · Australia (9) · United Kingdom (9) · Belgium (7) · Denmark (7) · Germany (6) · Japan (6) · Spain (6) · France (5) · Netherlands (5) · Norway (4)
Abeer Mohamed Elkholy, MD Dermatology (2) · Lindsay Burns, PhD (2) · Pankaj Arora, MD, FAHA (2) · Ahmed Abbas, MD (1) · Ahmed L Mohamed, Master (1) · Ahmed Walid Anwar Murad (1) · Alexander Mangushlo, MD (1) · Alexander Shvets, MD (1) · Alexandra Arias Mendoza, MD (1) · Alfredo Berruti (1)
PMID 15178665, PMID 16932650, PMID 18362143, PMID 18777528, PMID 19408036, PMID 19455472, PMID 19457631, PMID 20453709, PMID 21436587, PMID 22826385, PMID 24332218, PMID 24510426, PMID 24707463, PMID 24760244, PMID 24772219, PMID 24840045, PMID 25571842, PMID 25595796, PMID 25878120, PMID 25880846, PMID 26277847, PMID 26432046, PMID 27400947, PMID 27505637, PMID 27542885, PMID 27602993, PMID 28330649, PMID 28385284, PMID 28396734, PMID 28625918, PMID 28708070, PMID 29121415, PMID 29278279, PMID 29490031, PMID 29659896, PMID 29747074, PMID 30649458, PMID 31094901, PMID 31162140, PMID 31613965, PMID 31820199, PMID 32390277, PMID 32520623, PMID 33113596, PMID 33188449, PMID 33188747, PMID 33236103, PMID 33966452, PMID 34632308, PMID 34785545
2017 (3), 2018 (3), 2023 (3), 2015 (2), 2009 (1), 2016 (1), 2019 (1), 2025 (1), P20DA024157 (1), R01AG048349 (1), R01AG061091 (1), R01DK137207 (1), R01HL111659 (1), R01HL160982 (1), R01HL163852 (1)